Reuters logo
7 months ago
BRIEF-Corvus Pharmaceuticals announces expansion of renal cell carcinoma cohort in ongoing clinical study of lead checkpoint inhibitor CPI-444
January 10, 2017 / 3:15 PM / 7 months ago

BRIEF-Corvus Pharmaceuticals announces expansion of renal cell carcinoma cohort in ongoing clinical study of lead checkpoint inhibitor CPI-444

Jan 10 (Reuters) - Corvus Pharmaceuticals Inc

* Corvus Pharmaceuticals announces expansion of renal cell carcinoma cohort in ongoing phase 1/1b clinical study of lead checkpoint inhibitor CPI-444

* Cohort reached protocol-predefined criteria for expansion based on responses to single-agent treatment

* Could potentially initiate a registration trial before end of 2017

* To date, CPI-444 has been well tolerated when given orally twice daily. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below